Targeting Mutant KRAS for Anticancer Therapy.
Curr Top Med Chem
; 19(23): 2098-2113, 2019.
Article
em En
| MEDLINE
| ID: mdl-31475898
Over the past decades, designing therapeutic strategies to target KRAS-mutant cancers, which is one of the most frequent mutant oncogenes among all cancer types, have proven unsuccessful regardless of many concerted attempts. There are key challenges for KRAS-mutant anticancer therapy, as the complex cellular processes involved in KRAS signaling has present. Herein, we highlight the emerging therapeutic approaches for inhibiting KRAS signaling and blocking KRAS functions, in hope to serve as a more effective guideline for future development of therapeutics.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Proteína Oncogênica p21(ras)
/
Proteínas Proto-Oncogênicas p21(ras)
/
Neoplasias
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article